CC
MAZE

Casdin Capital’s Maze Therapeutics MAZE Stock Holding History

Casdin Capital’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.7M Hold
758,857
– – 1.72% 14
2025
Q4 		$31.4M Hold
758,857
– – 1.95% 11
2025
Q3 		$19.7M Hold
758,857
– – 1.64% 13
2025
Q2 		$9.31M Sell
758,857
-187,500
-20% -$1.95M 0.85% 17
2025
Q1 		$10.4M Buy
+946,357
New +$11.4M 0.85% 21

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Casdin Capital's MAZE Position: Q1 2026 in Review

Casdin Capital held its Maze Therapeutics (MAZE) position steady in Q1 2026 at 758,857 shares worth $22.7M. The position accounts for 1.72% of the portfolio, ranked #14.

Casdin Capital first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $31.4M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Casdin Capital held 758,857 shares of Maze Therapeutics worth $22.7M as of Q1 2026.
  • Casdin Capital left its Maze Therapeutics share count unchanged in Q1 2026.
  • Maze Therapeutics made up 1.72% of Casdin Capital's portfolio in Q1 2026, its #14 holding.
  • Casdin Capital first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Casdin Capital's Maze Therapeutics position peaked at $31.4M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.